MINT-RASAGILINE TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

RASAGILINE (RASAGILINE MESYLATE)

Disponibbli minn:

MINT PHARMACEUTICALS INC

Kodiċi ATC:

N04BD02

INN (Isem Internazzjonali):

RASAGILINE

Dożaġġ:

1MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

RASAGILINE (RASAGILINE MESYLATE) 1MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0151662002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2022-12-21

Karatteristiċi tal-prodott

_MINT-RASAGILINE _
_Page 1 of 45_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
MINT-RASAGILINE
Rasagiline Tablets
Tablet, 0.5 mg and 1 mg (as rasagiline mesylate), Oral
Professed Standard
Antiparkinson Agent
Mint Pharmaceuticals Inc.
6575 Davand Drive
Mississauga, Ontario
L5T 2M3
Date of Initial Authorization:
December 20, 2022
Submission Control Number: 250188
_ _
_MINT-RASAGILINE _
_Page 2 of 45_
RECENT MAJOR LABEL CHANGES
None at the time of authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................... 5
4
DOSAGE AND ADMINISTRATION
................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 5
4.4
Administration
.........................................................................................................
6
4.5
Missed Dose
........